Q You mentioned that the funding life cycle. I'm intrigued. I often speak to growth investors interested in, as you can imagine, consumer, fintech, enterprise, SaaS. I don't often come across Biotech and deep tech growth investors. Do you think that's a sufficient pool of capital moving forward for this deep tech innovations to really sustain them through their life cycle?
A I think a lot of money is moving into this space. So right now, this very moment, I think it's a little shaky, but in terms of us as seed investors, you know, we need to see what that landscape will look like two to three to four to five years from now. And when we see what the later stage investors are doing and we see a lot more later stage funds spinning up Biotech specific, either pools of capital or hiring biotech partners. We think that the transition is definitely heading that way. Even if you look at something early stage like Y Combinator, right, they have invested way more attention and resources into attracting and helping synthetic biology and biotech companies than they did four years ago. Four years ago, they weren't doing it at all.
AI assessment note: “we think that the transition is definitely heading that way.”